Therapeutic Cancer Vaccines: Past, Present, and Future

被引：400

作者：

Guo, Chunqing ^{[1
,2
,3
]}

Manjili, Masoud H. ^{[3
,4
]}

Subjeck, John R. ^{[5
]}

Sarkar, Devanand ^{[1
,2
,3
]}

Fisher, Paul B. ^{[1
,2
,3
]}

Wang, Xiang-Yang ^{[1
,2
,3
]}

机构：

[1] Virginia Commonwealth Univ, Dept Human & Mol Genet, Sch Med, Richmond, VA 23284 USA

[2] Virginia Commonwealth Univ, Sch Med, VCU Inst Mol Med, Richmond, VA USA

[3] Virginia Commonwealth Univ, Sch Med, VCU Massey Canc Ctr, Richmond, VA USA

[4] Virginia Commonwealth Univ, Dept Microbiol & Immunol, Sch Med, Richmond, VA 23298 USA

[5] Roswell Pk Canc Inst, Dept Cell Stress Biol, Buffalo, NY 14263 USA

来源：

ADVANCES IN CANCER RESEARCH, VOL 119 | 2013年 / 119卷

关键词：

COLONY-STIMULATING FACTOR; TUMOR-CELL VACCINE; HEAT-SHOCK-PROTEIN; REGULATORY T-CELLS; ACTIVE SPECIFIC IMMUNOTHERAPY; PHASE-II TRIAL; RESISTANT PROSTATE-CANCER; POTENT ANTITUMOR IMMUNITY; BACILLUS-CALMETTE-GUERIN; LYMPHOCYTE-ASSOCIATED ANTIGEN-4;

D O I：

10.1016/B978-0-12-407190-2.00007-1

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Therapeutic vaccines represent a viable option for active immunotherapy of cancers that aim to treat late stage disease by using a patient's own immune system. The promising results from clinical trials recently led to the approval of the first therapeutic cancer vaccine by the U.S. Food and Drug Administration. This major breakthrough not only provides a new treatment modality for cancer management but also paves the way for rationally designing and optimizing future vaccines with improved anticancer efficacy. Numerous vaccine strategies are currently being evaluated both preclinically and clinically. This review discusses therapeutic cancer vaccines from diverse platforms or targets as well as the preclinical and clinical studies employing these therapeutic vaccines. We also consider tumor-induced immune suppression that hinders the potency of therapeutic vaccines, and potential strategies to counteract these mechanisms for generating more robust and durable antitumor immune responses.

引用

页码：421 / 475

页数：55

共 405 条

[1] Phase I Study of the Humanized Anti-CD40 Monoclonal Antibody Dacetuzumab in Refractory or Recurrent Non-Hodgkin's Lymphoma [J].

Advani, Ranjana ;

Forero-Torres, Andres ;

Furman, Richard R. ;

Rosenblatt, Joseph D. ;

Younes, Anas ;

Ren, Hong ;

Harrop, Kate ;

Whiting, Nancy ;

Drachman, Jonathan G. .

JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (26) :4371-4377

[2] Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study [J].

Amato, Robert J. ;

Hawkins, Robert E. ;

Kaufman, Howard L. ;

Thompson, John A. ;

Tomczak, Piotr ;

Szczylik, Cezary ;

McDonald, Mike ;

Eastty, Sarah ;

Shingler, William H. ;

de Belin, Jackie ;

Goonewardena, Madusha ;

Naylor, Stuart ;

Harrop, Richard .

CLINICAL CANCER RESEARCH, 2010, 16 (22) :5539-5547

[3] Current status of immunological therapies for prostate cancer [J].

Antonarakis, Emmanuel S. ;

Drake, Charles G. .

CURRENT OPINION IN UROLOGY, 2010, 20 (03) :241-246

[4] Phase I trial of a B7-1 (CD80) gene modified autologous tumor cell vaccine in combination with systemic interleukin-2 in patients with metastatic renal cell carcinoma [J].

Antonia, SJ ;

Seigne, J ;

Diaz, J ;

Muro-Cacho, C ;

Extermann, M ;

Farmelo, MJ ;

Friberg, M ;

Alsarraj, M ;

Mahany, JJ ;

Pow-Sang, J ;

Cantor, A ;

Janssen, W .

JOURNAL OF UROLOGY, 2002, 167 (05) :1995-2000

[5] Toll-like receptor 4-dependent contribution of the immune system to anticancer chemotherapy and radiotherapy [J].

Apetoh, Lionel ;

Ghiringhelli, Francois ;

Tesniere, Antoine ;

Obeid, Michel ;

Ortiz, Carla ;

Criollo, Alfredo ;

Mignot, Gregoire ;

Maiuri, M. Chiara ;

Ullrich, Evelyn ;

Saulnier, Patrick ;

Yang, Huan ;

Amigorena, Sebastian ;

Ryffel, Bernard ;

Barrat, Franck J. ;

Saftig, Paul ;

Levi, Francis ;

Lidereau, Rosette ;

Nogues, Catherine ;

Mira, Jean-Paul ;

Chompret, Agnes ;

Joulin, Virginie ;

Clavel-Chapelon, Francoise ;

Bourhis, Jean ;

Andre, Fabrice ;

Delaloge, Suzette ;

Tursz, Thomas ;

Kroemer, Guido ;

Zitvogel, Laurence .

NATURE MEDICINE, 2007, 13 (09) :1050-1059

[6] mTOR regulates memory CD8 T-cell differentiation [J].

Araki, Koichi ;

Turner, Alexandra P. ;

Shaffer, Virginia Oliva ;

Gangappa, Shivaprakash ;

Keller, Susanne A. ;

Bachmann, Martin F. ;

Larsen, Christian P. ;

Ahmed, Rafi .

NATURE, 2009, 460 (7251) :108-U124

[7] A vaccine targeting angiomotin induces an antibody response which alters tumor vessel permeability and hampers the growth of established tumors [J].

Arigoni, Maddalena ;

Barutello, Giuseppina ;

Lanzardo, Stefania ;

Longo, Dario ;

Aime, Silvio ;

Curcio, Claudia ;

Iezzi, Manuela ;

Zheng, Yujuan ;

Barkefors, Irmeli ;

Holmgren, Lars ;

Cavallo, Federica .

ANGIOGENESIS, 2012, 15 (02) :305-316

[8]

Armstrong CA, 1996, CANCER RES, V56, P2191

[9] Androgen Ablation Augments Human HLA2.1-Restricted T cell Responses to PSA Self-Antigen in Transgenic Mice [J].

Arredouani, Mohamed S. ;

Tseng-Rogenski, Stephanie S. ;

Hollenbeck, Brent K. ;

Escara-Wilke, June ;

Leander, Karen R. ;

Defeo-Jones, Deborah ;

Hwang, Clara ;

Sanda, Martin G. .

PROSTATE, 2010, 70 (09) :1002-1011

[10] Significant antitumor effects obtained by autologous tumor cell vaccine engineered to secrete interleukin (IL)-12 and IL-18 by means of the EBV/lipoplex [J].

Asada, H ;

Kishida, T ;

Hirai, H ;

Satoh, E ;

Ohashi, S ;

Takeuchi, M ;

Kubo, T ;

Kita, M ;

Iwakura, Y ;

Imanishi, J ;

Mazda, O .

MOLECULAR THERAPY, 2002, 5 (05) :609-616

← 1 2 3 4 5 6 7 8 9 10 →